gefitinib has been researched along with zileuton in 6 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (zileuton) | Trials (zileuton) | Recent Studies (post-2010) (zileuton) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 551 | 64 | 193 |
| Protein | Taxonomy | gefitinib (IC50) | zileuton (IC50) |
|---|---|---|---|
| Prostaglandin E synthase | Homo sapiens (human) | 0.6 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | 1.4782 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | 0.9656 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Homo sapiens (human) | 0.4 | |
| Arachidonate 5-lipoxygenase-activating protein | Homo sapiens (human) | 0.58 | |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | 0.591 | |
| Polyunsaturated fatty acid 5-lipoxygenase | Mus musculus (house mouse) | 0.19 | |
| Leukotriene B4 receptor 1 | Homo sapiens (human) | 0.42 | |
| Cysteinyl leukotriene receptor 2 | Homo sapiens (human) | 0.42 | |
| Cysteinyl leukotriene receptor 1 | Homo sapiens (human) | 0.42 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Talele, TT | 1 |
1 review(s) available for gefitinib and zileuton
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for gefitinib and zileuton
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Acetylene Group, Friend or Foe in Medicinal Chemistry.
Topics: Acetylene; Alkynes; Animals; Anti-Inflammatory Agents; Chemistry, Pharmaceutical; Click Chemistry; Half-Life; HIV Reverse Transcriptase; HIV-1; Humans; Macrophages; Mice; Protein Kinase Inhibitors; Rats; Reverse Transcriptase Inhibitors | 2020 |